Identifying immune responses to vivax malaria using human antibodies

Defining targets of protective immunity to vivax malaria using human monoclonal antibodies

NIH-funded research Case Western Reserve University · NIH-10783019

This study is looking at how our immune system can fight off vivax malaria, and it’s for people interested in finding new ways to prevent and treat this serious illness by testing special antibodies from those who are immune.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionCase Western Reserve University NIH-funded
Lab location1 site (Cleveland, United States)
Project IDNIH-10783019 on NIH RePORTER

What this research studies

This research focuses on understanding how the human immune system can protect against vivax malaria, a widespread and severe form of malaria caused by the Plasmodium vivax parasite. The team aims to isolate specific human monoclonal antibodies from individuals who have developed immunity to this type of malaria. These antibodies will be tested to see if they can block the parasite's ability to invade liver and red blood cells, which is crucial for preventing infection and reducing disease severity. The research will involve laboratory experiments and animal models to evaluate the effectiveness of these antibodies and their potential for use in treatments.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals living in or originating from regions where vivax malaria is prevalent, particularly those who have experienced repeated infections.

Not a fit: Patients who do not reside in malaria-endemic areas or those who have never been exposed to vivax malaria may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new treatments and preventive measures for vivax malaria, potentially saving lives and improving health outcomes in affected populations.

How similar studies have performed: Previous research has shown promise in using monoclonal antibodies for malaria treatment, indicating that this approach could be effective.

Where this research is happening

Cleveland, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.